NASDAQ:IMMU - Immunomedics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $19.4250 +0.57 (+3.02 %) (As of 12/12/2018 11:18 AM ET)Previous Close$18.85Today's Range$18.78 - $19.8052-Week Range$11.82 - $27.33Volume419,895 shsAverage Volume2.15 million shsMarket Capitalization$3.35 billionP/E Ratio-18.86Dividend YieldN/ABeta1.88 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. Receive IMMU News and Ratings via Email Sign-up to receive the latest news and ratings for IMMU and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IMMU Previous Symbol CUSIP45290710 Webwww.immunomedics.com Phone973-605-8200 Debt Debt-to-Equity Ratio0.06 Current Ratio13.45 Quick Ratio13.45 Price-To-Earnings Trailing P/E Ratio-18.86 Forward P/E Ratio-16.19 P/E GrowthN/A Sales & Book Value Annual Sales$2.16 million Price / Sales1,712.55 Cash FlowN/A Price / Cash FlowN/A Book Value$2.39 per share Price / Book8.13 Profitability EPS (Most Recent Fiscal Year)($1.03) Net Income$-273,830,000.00 Net Margins-12,701.21% Return on Equity-85.57% Return on Assets-39.05% Miscellaneous Employees185 Outstanding Shares190,430,000Market Cap$3.35 billion OptionableOptionable Immunomedics (NASDAQ:IMMU) Frequently Asked Questions What is Immunomedics' stock symbol? Immunomedics trades on the NASDAQ under the ticker symbol "IMMU." How were Immunomedics' earnings last quarter? Immunomedics, Inc. (NASDAQ:IMMU) announced its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.06. Immunomedics had a negative net margin of 12,701.21% and a negative return on equity of 85.57%. During the same period in the prior year, the firm earned ($0.97) earnings per share. View Immunomedics' Earnings History. When is Immunomedics' next earnings date? Immunomedics is scheduled to release their next quarterly earnings announcement on Thursday, February 14th 2019. View Earnings Estimates for Immunomedics. What price target have analysts set for IMMU? 8 equities research analysts have issued 12 month target prices for Immunomedics' shares. Their forecasts range from $30.00 to $55.00. On average, they expect Immunomedics' stock price to reach $37.3750 in the next year. This suggests a possible upside of 89.4% from the stock's current price. View Analyst Price Targets for Immunomedics. What is the consensus analysts' recommendation for Immunomedics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics. Has Immunomedics been receiving favorable news coverage? Media headlines about IMMU stock have been trending positive on Wednesday, InfoTrie reports. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Immunomedics earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. Are investors shorting Immunomedics? Immunomedics saw a increase in short interest in the month of November. As of November 30th, there was short interest totalling 25,615,055 shares, an increase of 9.5% from the November 15th total of 23,387,470 shares. Based on an average daily trading volume, of 2,064,602 shares, the days-to-cover ratio is presently 12.4 days. Currently, 15.1% of the company's shares are short sold. View Immunomedics' Current Options Chain. Who are some of Immunomedics' key competitors? Some companies that are related to Immunomedics include IPSEN S A/S (IPSEY), Neogen (NEOG), Myriad Genetics (MYGN), Quidel (QDEL), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Lantheus (LNTH), Oxford Immunotec Global (OXFD), Quotient (QTNT), Nymox Pharmaceutical (NYMX), Trinity Biotech (TRIB), Celldex Therapeutics (CLDX), ImmuCell (ICCC), Vermillion (VRML) and Riot Blockchain (RIOT). Who are Immunomedics' key executives? Immunomedics' management team includes the folowing people: Mr. Michael F. Pehl, Pres, CEO & Director (Age 53)Dr. Morris Z. Rosenberg, Chief Technology Officer (Age 58)Mr. Brendan Delaney, Chief Commercial Officer (Age 43)Dr. Robert Iannone, Chief Medical Officer and Head of R&D (Age 51)Mr. Michael R. Garone, VP of Fin. (Age 59) Who are Immunomedics' major shareholders? Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.44%), BlackRock Inc. (6.42%), FMR LLC (2.93%), Janus Henderson Group PLC (1.92%), Foresite Capital Management III LLC (1.42%) and Jennison Associates LLC (1.14%). Company insiders that own Immunomedics stock include Behzad Aghazadeh, Brian A Markison, Cynthia L Goldenberg, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics. Which institutional investors are selling Immunomedics stock? IMMU stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Acuta Capital Partners LLC, Pictet Asset Management Ltd., Alliancebernstein L.P., Seven Eight Capital LP, Victory Capital Management Inc., Axiom International Investors LLC DE and EAM Investors LLC. View Insider Buying and Selling for Immunomedics. Which institutional investors are buying Immunomedics stock? IMMU stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., BlackRock Inc., American Century Companies Inc., Deutsche Bank AG, Renaissance Technologies LLC, Janus Henderson Group PLC, Sphera Funds Management LTD. and Allianz Asset Management GmbH. Company insiders that have bought Immunomedics stock in the last two years include Behzad Aghazadeh and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics. How do I buy shares of Immunomedics? Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Immunomedics' stock price today? One share of IMMU stock can currently be purchased for approximately $19.73. How big of a company is Immunomedics? Immunomedics has a market capitalization of $3.35 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,830,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 185 workers across the globe. What is Immunomedics' official website? The official website for Immunomedics is http://www.immunomedics.com. How can I contact Immunomedics? Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected] MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 281 (Vote Outperform)Underperform Votes: 248 (Vote Underperform)Total Votes: 529MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe IMMU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMMU will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/12/2018 by MarketBeat.com StaffFeatured Article: Why do earnings reports matter?